The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 26, 2022

Filed:

Aug. 31, 2021
Applicant:

Elixiron Immunotherapeutics (Hong Kong) Limited, Hong Kong, CN;

Inventors:

Hung-Kai Chen, Los Altos, CA (US);

Daw-Tsun Shih, Taipei, TW;

Jing-Yi Huang, Taipei, TW;

Huey-Wen Hsiao, Taipei, TW;

Chih-Lun Hsiao, Taipei, TW;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2866 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present disclosure provides antibodies, including antibody fusions, which specifically bind to human CSF1 receptor protein (huCSF1R) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by huCSF1R, such as regulation of TAMs in the tumor microenvironment. Additionally, the antibodies include fusions with the cytokine inhibitory factor, IL10, which can replenish and/or activate CD8+ T-cell cytotoxicity in the tumor microenvironment. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CSF1 binding to CSF1R.


Find Patent Forward Citations

Loading…